Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients - A systematic review and network meta-analysis

Comparing diabetes drugs head-to-head across trials, this network meta-analysis found SGLT2 inhibitors gave the strongest kidney and heart-failure protection in patients with diabetes and CKD, with GLP-1 agonists next; both lowered death rates while DPP-4 inhibitors added little.